Invited Review: Carcinogenicity Assessments of Biotechnology-Derived Pharmaceuticals: A Review of Approved Molecules and Best Practice Recommendations.

MLA

Vahle, John L., et al. “Invited Review: Carcinogenicity Assessments of Biotechnology-Derived Pharmaceuticals: A Review of Approved Molecules and Best Practice Recommendations.” Toxicologic Pathology, vol. 38, no. 4, June 2010, pp. 522–53. EBSCOhost, https://doi.org/10.1177/0192623310368984.

APA

Vahle, J. L., Finch, G. L., Heidel, S. M., Hovland Jr., D. N., Ivens, I., Parker, S., Ponce, R. A., Sachs, C., Steigerwalt, R., Short, B., & Todd, M. D. (2010). Invited Review: Carcinogenicity Assessments of Biotechnology-Derived Pharmaceuticals: A Review of Approved Molecules and Best Practice Recommendations. Toxicologic Pathology, 38(4), 522–553. https://doi.org/10.1177/0192623310368984

Chicago

Vahle, John L., Gregory L. Finch, Shawn M. Heidel, David N. Hovland Jr., Inge Ivens, Suezanne Parker, Rafael A. Ponce, et al. 2010. “Invited Review: Carcinogenicity Assessments of Biotechnology-Derived Pharmaceuticals: A Review of Approved Molecules and Best Practice Recommendations.” Toxicologic Pathology 38 (4): 522–53. doi:10.1177/0192623310368984.